within Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EA05_Brimonidine;

model Brimonidine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 8.333333333333334e-06,
    adminDuration = 600,
    adminMass = 0.2 / 1000000,
    adminCount = 1,
    Vd = 0.01,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Brimonidine</td></tr><tr><td>ATC code:</td><td>S01EA05</td></tr><td>route:</td><td>ophthalmic</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10</td><td>L</td></tr>
    <tr><td>clearance:</td><td>500</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Brimonidine is an alpha-2 adrenergic receptor agonist primarily used in ophthalmology for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is approved and widely used as an eye drop for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after topical ophthalmic administration of brimonidine in healthy adult subjects.</p><h4>References</h4><ol><li><p>Ackerman, SL, et al., &amp; Vittitow, JL (2019). Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials. <i>Clinical &amp; experimental optometry</i> 102(2) 131–139. DOI:<a href=\"https://doi.org/10.1111/cxo.12846\">10.1111/cxo.12846</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30525235/\">https://pubmed.ncbi.nlm.nih.gov/30525235</a></p></li><li><p>Schnichels, S, et al., &amp; Herrmann, A (2021). Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles. <i>ACS applied materials &amp; interfaces</i> 13(8) 9445–9456. DOI:<a href=\"https://doi.org/10.1021/acsami.0c18626\">10.1021/acsami.0c18626</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33528240/\">https://pubmed.ncbi.nlm.nih.gov/33528240</a></p></li><li><p>Kim, CY, et al., &amp; Seong, GJ (2007). Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 23(5) 481–486. DOI:<a href=\"https://doi.org/10.1089/jop.2007.0042\">10.1089/jop.2007.0042</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17900227/\">https://pubmed.ncbi.nlm.nih.gov/17900227</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01EA05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Brimonidine;
